Vividion Therapeutics

Vividion Therapeutics is transforming the future of human health by creating highly selective small molecule drugs that target traditionally difficult-to-drug targets. It is advancing a broad and diverse pipeline of selective small molecule therapies for multiple highly sought-after disease-modifying target proteins in oncology and immunology. Vividion Therapeutics' approach leverages deep expertise in chemistry, mass spectrometry, and drug development to identify highly selective hits through its screening platform and small molecule library. This method facilitates the discovery of ligands for novel pockets across multiple protein targets, which can then be developed into transformative small molecule therapies. The company is developing a range of therapeutic candidates with high selectivity for proteins that play critical roles in disease pathways and have the potential to address a wide array of unmet medical needs.